Disc Medicine, Inc. 8K

Disc Medicine reported Q2 2026 results, reaffirmed a strong cash position, and detailed significant regulatory and clinical progress across its bitopertin, selcodebart, and DISC-3405 programs.

Disc Medicine, Inc. filed a current report to announce its second quarter 2026 financial results and provide a business update, highlighting completion of a Type A meeting with the FDA for bitopertin in erythropoietic protoporphyria (EPP) that aligned on the Phase 3 APOLLO trial as the basis for a complete response letter (CRL) resubmission and potential traditional approval, launch of an Expanded Access Program for bitopertin in EPP and XLP, positive updated clinical data from the RALLY-MF Phase 2 trial of selcodebart (DISC-0974) in myelofibrosis anemia and continued development in inflammatory bowel disease, and progress of DISC-3405 with full enrollment of the RESTORE-PV Phase 2 polycythemia vera study and advancement of a Phase 1b sickle cell disease study. The company reported Q2 2026 cash, cash equivalents, and marketable securities of approximately $717.7 million, which it expects to fund operations into 2029, along with research and development expenses of $46.9 million, selling, general and administrative expenses of $18.1 million, and a net loss of $59.5 million for the quarter, reflecting ongoing investment in its hematology-focused pipeline.

Filing Facts

CIK

1816736

Ticker

IRON

Form

8K

Source Type

fda

Accession

0001193125-26-325031

Alert Tier

6